<PAGE>
----------------------------
OMB APPROVAL
----------------------------
OMB Number: 3235-0415
Expires: October 31, 1997
Estimated average burden
hours per response.... 14.90
----------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
Microfluidics International Corporation
(formerly Biotechnology Development Corporation)
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
595073107
- --------------------------------------------------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 595073107 13G PAGE 2 OF 5 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Irwin J. Gruverman
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
United States of America
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF
382,300
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
OWNED BY 424,505
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING
382,300
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
424,505
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
806,805, including 222,300 shares and 160,000 options exercisable within
60 days owned directly by Mr. Gruverman, and 424,505 shares owned jointly
by Mr. Gruverman and his wife.
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
10 CERTAIN SHARES* [_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11
15.4%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
IN
- ------------------------------------------------------------------------------
<PAGE>
Item 1(a) Name of Issuer
--------------
Microfluidics International Corporation
(formerly Biotechnology Development Corporation)
Item 1(b) Address of Issuer's Principal Executive Offices
-----------------------------------------------
30 Ossipee Road, Newton, MA 02164
Item 2(a) Name of Person Filing
---------------------
Irwin J. Gruverman
Item 2(b) Address of Principal Business Office or, if none, Residence
-----------------------------------------------------------
Microfluidics International Corp., 30 Ossipee Rd.,
Newton, MA 02164
Item 2(c) State of Organization/Citizenship
---------------------------------
United States of America
Item 2(d) Title of Class of Securities
----------------------------
Common Stock
Item 2(e) CUSIP Number
------------
595073107
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-
-------------------------------------------------------------
2(b), check whether the person filing is a
------------------------------------------
(a) [ ] Broker or Dealer registered under Section 15 of the Act
(b) [ ] Bank as defined in Section 3(a)(6) of the Act
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the
Act
(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act
Page 3 of 5 pages
<PAGE>
(e) [ ] Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940
(f) [ ] Employee Benefit Plan, Pension Fund which is subject to
the provisions of the Employee Retirement Income Security
Act of 1974 or Endowment Fund; see S240.13d-1(b)(1)(ii)(F)
(g) [ ] Parent Holding Company, in accordance with S240.13d-
1(b)(1)(ii)(G)
(h) [ ] Group, in accordance with S240.13d-1(b)(1)(ii)(H)
Not applicable.
Item 4. Ownership
---------
(a) Amount Beneficially Owned: Mr. Gruverman beneficially owns an
aggregate of 806,805 shares of common stock, including
160,000 options exercisable within 60 days of the date
hereof owned directly by Mr. Gruverman, and 424,505 shares
owned jointly by Mr. Gruverman and his wife.
(b) Percent of Class: 15.4%
(c) Number of shares as to which such person has:
<TABLE>
<C> <S> <C>
(i) sole power to vote or to direct the vote: 382,300
(ii) shared power to vote or to direct the vote: 424,505
(iii) sole power to dispose or to direct the disposition of: 382,300
(iv) shared power to dispose or to direct the disposition of: 424,505
</TABLE>
Item 5. Ownership of Five Percent or Less of a Class
--------------------------------------------
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person
---------------------------------------------------------------
Not applicable.
Page 4 of 5 pages
<PAGE>
Item 7. Identification and Classification of the Subsidiary Which
---------------------------------------------------------
Acquired the Security Being Reported on By the Parent Holding
-------------------------------------------------------------
Company
-------
Not applicable.
Item 8. Identification and Classification of Members of the Group
---------------------------------------------------------
Not applicable.
Item 9. Notice of Dissolution of Group
------------------------------
Not applicable.
Item 10. Certification
-------------
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the ordinary
course of business and were not acquired for the purpose of and do not
have the effect of changing or influencing the control of the issuer
of such securities and were not acquired in connection with or as a
participant in any transaction having such purposes or effect.
Signature
---------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: April 14, 1997 /s/ Irwin J. Gruverman
-------------------------------------
Irwin J. Gruverman
Microfluidics International Corporation
Chairman of the Board, Chief Executive
Officer and Secretary
Page 5 of 5 pages
<PAGE>
----------------------------
PURSUANT TO RULE 13D-2(C) PROMULGATED OMB APPROVAL
UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED, RESTATED BELOW IS THE ENTIRE -----------------------------
TEXT OF THE SCHEDULE 13G FILED BY OMB Number: 3235-0415
MR. GRUVERMAN ON FEBRUARY 12, 1993. Expires: October 31, 1997
Estimated average burden
hours per response.... 14.90
----------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. )*
Biotechnology Development Corporation
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
090918-10-3
- --------------------------------------------------------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement [ ]. (A fee
is not required only if the filing person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 090918-10-3 13G PAGE 2 OF 5 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Irwin J. Gruverman
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
United States
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF
769,456
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
OWNED BY 33,250
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING
769,456
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
33,250
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
861,456
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
10 CERTAIN SHARES* [_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11
21.6%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
IN
- ------------------------------------------------------------------------------
<PAGE>
Item 1(a) Name of Issuer
--------------
Biotechnology Development Corporation
Item 1(b) Address of Issuer's Principal Executive Offices
-----------------------------------------------
90 Oak Street, Newton, Massachusetts 02164
Item 2(a) Name of Person Filing
---------------------
Irwin J. Gruverman
Item 2(b) Address of Principal Business Office or, if none, Residence
-----------------------------------------------------------
c/o Biotechnology Development Corporation,
90 Oak Street, Newton, Massachusetts 02164
Item 2(c) State of Organization/Citizenship
---------------------------------
Mr. Gruverman is a United States citizen
Item 2(d) Title of Class of Securities
----------------------------
Common Stock, $.01 par value per share
Item 2(e) CUSIP Number
------------
090918-10-3
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-
-------------------------------------------------------------
2(b), check whether the person filing is a
------------------------------------------
(a) [ ] Broker or Dealer registered under Section 15 of the Act
(b) [ ] Bank as defined in Section 3(a)(6) of the Act
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the
Act
(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act
(e) [ ] Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940
(f) [ ] Employee Benefit Plan, Pension Fund which is subject to
the provisions of the Employee Retirement Income Security
Act of 1974 or Endowment Fund; see S240.13d-1(b)(1)(ii)(F)
(g) [ ] Parent Holding Company, in accordance with S240.13d-
1(b)(1)(ii)(G)
(h) [ ] Group, in accordance with S240.13d-1(b)(1)(ii)(H)
Not applicable.
CUSIP Number: 090918-10-3 Page 3 of 5 pages
<PAGE>
Item 4. Ownership
---------
(a) Amount Beneficially Owned: Mr. Gruverman beneficially owns an
802,706 shares of Common Stock. This includes 33,250 shares
of common stock owned jointly by Mr. Gruverman and his wife
and includes options to purchase 248,000 shares of Common
Stock which were exercisable at December 31, 1992 or within
60 days thereafter.
(b) Percent of Class: 15.4%
(c) Number of shares as to which such person has:
<TABLE>
<C> <S> <C>
(i) sole power to vote or to direct the vote: 769,456
(ii) shared power to vote or to direct the vote: 33,250
(iii) sole power to dispose or to direct the disposition of: 769,456
(iv) shared power to dispose or to direct the disposition of: 33,250
</TABLE>
Item 5. Ownership of Five Percent or Less of a Class
--------------------------------------------
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person
---------------------------------------------------------------
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
---------------------------------------------------------
Acquired the Security Being Reported on By the Parent Holding
-------------------------------------------------------------
Company
-------
Not applicable.
Item 8. Identification and Classification of Members of the Group
---------------------------------------------------------
Not applicable.
Item 9. Notice of Dissolution of Group
------------------------------
Not applicable.
CUSIP Number: 090918-10-3 Page 4 of 5 pages
<PAGE>
Item 10. Certification
-------------
Not applicable. This statement on Schedule 13G is not filed pursuant
to Rule 13d-1(b).
Signature
---------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: February 12, 1993 /s/ Irwin J. Gruverman
-------------------------------------
Irwin J. Gruverman
CUSIP Number: 090918-10-3 Page 5 of 5 pages
